Incredible! HEC Pharma won 5.6 billion major varieties
2022-11-07
Source: Menet.com
Insulin Aspart 30 Injection is a premixed insulin containing 30% soluble insulin aspart and 70% protamine insulin aspart. Insulin aspart 30 injection is suitable for the treatment of diabetes. It can be injected with meals, and its glycosylated hemoglobin (Hb A1c) compliance rate is higher, which can better control postprandial blood sugar.
According to data from Menet.com, in 2021, Chinese urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) sold nearly 29 billion yuan of terminal insulin and similar drugs, a year-on-year increase of 5.81%. Among them, the sales volume of insulin aspart 30 injection exceeded 5.6 billion yuan, a year-on-year increase of 1.15%.
Sales of terminal insulin aspart 30 injection in Chinese public medical institutions (unit: ten thousand yuan)
Source: Menet.com Chinese public medical institutions drug terminal competition landscape
It is worth mentioning that on October 11, HEC Pharma’s insulin aspart injection was approved for marketing, making it the fifth domestic company. In less than a month, HEC has harvested two third-generation insulin analogs.
HEC Pharma previously approved insulin products
Source: new version database of Menet.com
So far, HEC Pharma has 4 insulin products approved for marketing, including human insulin injection, insulin glargine injection, insulin aspart injection, and insulin aspart 30 injection. In addition, the marketing application of protamine-human insulin mixed injection (30R) is under review and is expected to be approved for marketing in 2023.
HEC Pharma has been deeply involved in the field of diabetes treatment for a long time, and has laid out a complete product line, including biguanides, sulfonylureas, DPP4 inhibitors, insulin analogs, SGLT2 inhibitor innovative drugs, diabetes macromolecule innovative drugs, etc.
Data source: Menet.com database
Note: Menet.com “Chinese public medical institutions drug terminal competition landscape”. The statistical scope is: Chinese urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, and village clinics; the above sales are calculated based on the average retail price of the product in the terminal.
Read original article：https://mp.weixin.qq.com/s/fb8a4M5yWQtq5V4OEs37wQ
Related news
WeChat public account
2022 Copyright by HEC Group 粵ICP備19034764號(hào)-1